Certara Inc
NASDAQ:CERT
Intrinsic Value
Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. [ Read More ]
The intrinsic value of one CERT stock under the Base Case scenario is 10.42 USD. Compared to the current market price of 16.21 USD, Certara Inc is Overvalued by 36%.
Valuation Backtest
Certara Inc
Run backtest to discover the historical profit from buying and selling CERT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Certara Inc
Current Assets | 340.2m |
Cash & Short-Term Investments | 235m |
Receivables | 93.3m |
Other Current Assets | 12m |
Non-Current Assets | 1.2B |
PP&E | 12.3m |
Intangibles | 1.2B |
Other Non-Current Assets | 7.3m |
Current Liabilities | 130m |
Accounts Payable | 5.2m |
Accrued Liabilities | 41.7m |
Other Current Liabilities | 83.1m |
Non-Current Liabilities | 386.3m |
Long-Term Debt | 288.2m |
Other Non-Current Liabilities | 98.1m |
Earnings Waterfall
Certara Inc
Revenue
|
354.3m
USD
|
Cost of Revenue
|
-141m
USD
|
Gross Profit
|
213.3m
USD
|
Operating Expenses
|
-207.1m
USD
|
Operating Income
|
6.2m
USD
|
Other Expenses
|
-61.6m
USD
|
Net Income
|
-55.4m
USD
|
Free Cash Flow Analysis
Certara Inc
What is Free Cash Flow?
CERT Profitability Score
Profitability Due Diligence
Certara Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Score
Certara Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
CERT Solvency Score
Solvency Due Diligence
Certara Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Score
Certara Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CERT Price Targets Summary
Certara Inc
According to Wall Street analysts, the average 1-year price target for CERT is 20.12 USD with a low forecast of 15.66 USD and a high forecast of 24.15 USD.
Ownership
CERT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CERT Price
Certara Inc
Average Annual Return | -4.31% |
Standard Deviation of Annual Returns | 44.11% |
Max Drawdown | -76% |
Market Capitalization | 2.7B USD |
Shares Outstanding | 160 191 008 |
Percentage of Shares Shorted | 4.75% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. The company is headquartered in Princeton, New Jersey and currently employs 1,054 full-time employees. The company went IPO on 2020-12-11. The firm is focused on producing medicines for patients using biosimulation software and technology to transform traditional drug discovery and development. Biosimulation is a technology used to conduct virtual trials using virtual patients to better understand how drugs behave in different individuals. The firm builds its biosimulation technology on the first principles of biology, chemistry, and pharmacology with mathematical algorithms that model how medicines and diseases behave in the body. Its software and technology-enabled services include Mechanistic Biosimulation Platform (Simcyp); Empirical Pharmacokinetic and Pharmacodynamic Biosimulation (Phoenix); Scientific Informatics Platform (D360); Clinical Outcomes Databases for Biosimulation (CODEx); Authoring and Management of Regulatory Submissions Platform (GlobalSubmit), And Market Access Communication Platform (BaseCase).
Contact
IPO
Employees
Officers
The intrinsic value of one CERT stock under the Base Case scenario is 10.42 USD.
Compared to the current market price of 16.21 USD, Certara Inc is Overvalued by 36%.